Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Response to Gammal et al.

Vassy JL, Stone A, Callaghan JT, Mendes M, Meyer LJ, Pratt VM, Przygodzki RM, Scheuner MT, Wang-Rodriguez J, Schichman SA; VHA Clinical Pharmacogenetics Subcommittee.

Genet Med. 2019 Aug;21(8):1888-1889. doi: 10.1038/s41436-018-0422-9. Epub 2019 Jan 12. No abstract available.

PMID:
30635623
2.

Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.

Vassy JL, Stone A, Callaghan JT, Mendes M, Meyer LJ, Pratt VM, Przygodzki RM, Scheuner MT, Wang-Rodriguez J, Schichman SA; VHA Clinical Pharmacogenetics Subcommittee.

Genet Med. 2019 Feb;21(2):382-390. doi: 10.1038/s41436-018-0057-x. Epub 2018 Jun 1.

3.

Multilayer Nanoscale Encapsulation of Biofunctional Peptides to Enhance Bone Tissue Regeneration In Vivo.

Gentile P, Ferreira AM, Callaghan JT, Miller CA, Atkinson J, Freeman C, Hatton PV.

Adv Healthc Mater. 2017 Apr;6(8). doi: 10.1002/adhm.201601182. Epub 2017 Feb 7.

4.

Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.

5.

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP.

Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606.

6.

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.

Eadon MT, Desta Z, Levy KD, Decker BS, Pierson RC, Pratt VM, Callaghan JT, Rosenman MB, Carpenter JS, Holmes AM, McDonald CA, Benson EA, Patil AS, Vuppalanchi R, Gufford BT, Dave N, Robarge JD, Hyder MA, Haas DM, Kreutz RP, Dexter PR, Skaar TC, Flockhart DA.

Clin Pharmacol Ther. 2016 Jul;100(1):63-6. doi: 10.1002/cpt.347. Epub 2016 Mar 31. Review.

7.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Jan;99(1):36-7. doi: 10.1002/cpt.161. Epub 2015 Jul 16.

8.

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.

Metzger IF, Quigg TC, Epstein N, Aregbe AO, Thong N, Callaghan JT, Flockhart DA, Nguyen AT, Stevens CK, Gupta SK, Desta Z.

Curr Ther Res Clin Exp. 2014 Sep 27;76:64-9. doi: 10.1016/j.curtheres.2014.05.002. eCollection 2014 Dec.

9.

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.

10.

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Sep;24(9):464-76. doi: 10.1097/FPC.0000000000000058. Review. No abstract available.

11.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23. Review.

12.

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT.

Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.

13.

Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions.

Duke JD, Han X, Wang Z, Subhadarshini A, Karnik SD, Li X, Hall SD, Jin Y, Callaghan JT, Overhage MJ, Flockhart DA, Strother RM, Quinney SK, Li L.

PLoS Comput Biol. 2012;8(8):e1002614. doi: 10.1371/journal.pcbi.1002614. Epub 2012 Aug 9.

14.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2012 Feb;91(2):321-6. doi: 10.1038/clpt.2011.287. Epub 2011 Dec 28.

15.

Polymer-hydroxyapatite composite versus polymer interference screws in anterior cruciate ligament reconstruction in a large animal model.

Hunt JA, Callaghan JT.

Knee Surg Sports Traumatol Arthrosc. 2008 Jul;16(7):655-60. doi: 10.1007/s00167-008-0528-8. Epub 2008 Apr 17.

PMID:
18418577
16.

The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.

Derby MA, Zhang L, Chappell JC, Gonzales CR, Callaghan JT, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Mitchell MI.

J Cardiovasc Pharmacol. 2007 Jun;49(6):384-93.

PMID:
17577103
17.

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M.

J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53.

PMID:
17414226
18.

The design and production of Co-Cr alloy implants with controlled surface topography by CAD-CAM method and their effects on osseointegration.

Hunt JA, Callaghan JT, Sutcliffe CJ, Morgan RH, Halford B, Black RA.

Biomaterials. 2005 Oct;26(29):5890-7. Epub 2005 Apr 15.

PMID:
15949554
19.

The physical properties and response of osteoblasts to solution cast films of PLGA doped polycaprolactone.

Tang ZG, Callaghan JT, Hunt JA.

Biomaterials. 2005 Nov;26(33):6618-24.

PMID:
15935466
20.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2003 Nov 15;9(15):5540-9.

21.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER).

Drug Metab Dispos. 2003 Jul;31(7):815-32.

PMID:
12814957
22.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups.

J Clin Pharmacol. 2003 May;43(5):443-69. Review.

PMID:
12751267
23.

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD.

Br J Clin Pharmacol. 2002 Jan;53(1):67-74.

24.

Confidence interval criteria for assessment of dose proportionality.

Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST.

Pharm Res. 2000 Oct;17(10):1278-83.

PMID:
11145235
25.

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM.

Clin Pharmacokinet. 1999 Sep;37(3):177-93. Review.

PMID:
10511917
26.

Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.

Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callaghan JT.

Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48.

PMID:
9855322
27.

Olanzapine: interaction study with imipramine.

Callaghan JT, Cerimele BJ, Kassahun KJ, Nyhart EH Jr, Hoyes-Beehler PJ, Kondraske GV.

J Clin Pharmacol. 1997 Oct;37(10):971-8.

PMID:
9505989
28.

Disposition and biotransformation of the antipsychotic agent olanzapine in humans.

Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L.

Drug Metab Dispos. 1997 Jan;25(1):81-93.

PMID:
9010634
29.

Role of serum prolactin determination in evaluation of impotent patient.

Foster RS, Mulcahy JJ, Callaghan JT, Crabtree R, Brashear D.

Urology. 1990 Dec;36(6):499-501.

PMID:
2247915
30.

Disposition in humans of racemic picenadol, an opioid analgesic.

Franz PM, Anliker SL, Callaghan JT, DeSante KA, Dhahir PH, Nelson RL, Rubin A.

Drug Metab Dispos. 1990 Nov-Dec;18(6):968-73.

PMID:
1981546
31.

Secretion of nizatidine into human breast milk after single and multiple doses.

Obermeyer BD, Bergstrom RF, Callaghan JT, Knadler MP, Golichowski A, Rubin A.

Clin Pharmacol Ther. 1990 Jun;47(6):724-30.

PMID:
1972674
32.

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion.

Schneck DW, Callaghan JT, Bergstrom RF, Obermeyer BD, Offen WW.

Clin Pharmacol Ther. 1990 Apr;47(4):499-503.

PMID:
2109665
33.

Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics.

Israel E, Juniper EF, Callaghan JT, Mathur PN, Morris MM, Dowell AR, Enas GG, Hargreave FE, Drazen JM.

Am Rev Respir Dis. 1989 Nov;140(5):1348-53.

PMID:
2817597
34.

In-flight medical emergencies. One year of experience with the enhanced medical kit.

Cottrell JJ, Callaghan JT, Kohn GM, Hensler EC, Rogers RM.

JAMA. 1989 Sep 22-29;262(12):1653-6.

PMID:
2769920
35.

Nizatidine disposition in subjects with normal and impaired renal function.

Aronoff GR, Bergstrom RF, Bopp RJ, Sloan RS, Callaghan JT.

Clin Pharmacol Ther. 1988 Jun;43(6):688-95.

PMID:
2897890
36.

Double-blind comparator trials with pinacidil, a potassium channel opener.

Callaghan JT, Goldberg MR, Brunelle R.

Drugs. 1988;36 Suppl 7:77-82.

PMID:
3076139
37.

Absorption studies of the H2-blocker nizatidine.

Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A.

Clin Pharmacol Ther. 1987 Nov;42(5):514-20. Erratum in: Clin Pharmacol Ther 1991 Mar;49(3):255.

PMID:
2890459
38.

Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.

Callaghan JT, Rubin A, Knadler MP, Bergstrom RF.

J Clin Pharmacol. 1987 Aug;27(8):618-24.

PMID:
2888796
39.

A pharmacokinetic profile of nizatidine in man.

Callaghan JT, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G, et al.

Scand J Gastroenterol Suppl. 1987;136:9-17. Review. Erratum in: Scand J Gastroenterol Suppl 1991 Aug;26(8):preceding 801.

PMID:
2892261
40.

Nizatidine, an H2-blocker. Its metabolism and disposition in man.

Knadler MP, Bergstrom RF, Callaghan JT, Rubin A.

Drug Metab Dispos. 1986 Mar-Apr;14(2):175-82.

PMID:
2870891
41.

Intravenous nizatidine kinetics and acid suppression.

Callaghan JT, Bergstrom RF, Obermeyer BD, King EP, Offen WW.

Clin Pharmacol Ther. 1985 Feb;37(2):162-5.

PMID:
2857117
42.

Correlation of in vivo and in vitro expression of cell-mediated immunity to mumps skin test antigen.

Petersen BH, Callaghan JT, Steimel LA, Epinette WW.

J Allergy Clin Immunol. 1983 Jun;71(6):612-7.

PMID:
6343463
43.

Suppression of mitogen-induced lymphocyte transformation in cigarette smokers.

Petersen BH, Steimel LF, Callaghan JT.

Clin Immunol Immunopathol. 1983 Apr;27(1):135-40.

PMID:
6872351
44.

Effect of cholestyramine and colestipol on the absorption of phenytoin.

Callaghan JT, Tsuru M, Holtzman JL, Hunninghake DB.

Eur J Clin Pharmacol. 1983;24(5):675-8.

PMID:
6873150
45.

Delayed hypersensitivity to mumps antigen in humans.

Callaghan JT, Petersen BH, Smith WC, Epinette WW, Ransburg RC.

Clin Immunol Immunopathol. 1983 Jan;26(1):102-10.

PMID:
6347480
46.

CSF perfusion to treat intraventricular penicillin toxicity.

Callaghan JT, Ausman JI, Clubb R.

Arch Neurol. 1981 Jun;38(6):390-1.

PMID:
7236074
47.

Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative.

Callaghan JT, Cleary RE, Crabtree R, Lemberger L.

Life Sci. 1981 Jan 5;28(1):95-102. No abstract available.

PMID:
7194408
48.

Pergolide, a potent long-acting dopamine-receptor agonist.

Lemberger L, Crabtree R, Callaghan JT.

Clin Pharmacol Ther. 1980 May;27(5):642-51.

PMID:
7189453

Supplemental Content

Loading ...
Support Center